Management Team

Mr Pursglove , is an accomplished executive and entrepreneur with more than a decade of experience spanning mergers and acquisitions, public and private capital markets, strategic growth initiatives, and operational leadership. Throughout his career, he has worked across a diverse range of industries, including technology, logistics, customer experience, sports, and marketing, successfully leading organizations through periods of growth, transformation, and value creation. He has built a strong reputation for identifying emerging opportunities, executing complex transactions, and developing scalable business platforms that support long-term success. Drawing on extensive experience in both public and private market environments, Mr. Pursglove has been actively involved in capital raising, corporate development, strategic partnerships, and business optimization efforts. His entrepreneurial approach and forward-thinking leadership style have enabled him to drive innovation, improve operational performance, and position organizations for sustainable growth. He is particularly recognized for his ability to align strategic vision with disciplined execution, helping companies navigate evolving market dynamics while creating lasting stakeholder value. In addition to his executive leadership responsibilities, Mr. Pursglove serves on the Board of Directors of GridAI (Nasdaq: GRDX), where he contributes his expertise in corporate strategy, governance, capital markets, and growth initiatives. His combination of entrepreneurial insight, operational expertise, and transaction experience continues to make him a trusted advisor and leader across a broad spectrum of industries and business stages.

Mr. van der Baan, 51, has more than 20 years of experience in the biotechnology industry, with a key focus on oncology and diagnostics. Most recently, he was the Chief Clinical and Business Development Officer of Agendia, Inc. in Irvine, California and Amsterdam, Netherlands. In that role, Mr. van der Baan was instrumental in the initiation and execution of numerous clinical trials that led to full commercialization and adoption of precision molecular oncology diagnostics. He initiated the launch of Agendia’s business operations in the United States and has broad knowhow in clinical development, both in the United States and in Europe.

Peter Stazzone brings to LIXTE more than 20 years of relevant financial management experience in publicly traded and privately owned companies, where he has been instrumental in guiding corporate transformations, including M&A, raising capital, implementing financial controls, and managing the public company reporting process. He has served as CFO for several companies, including Beyond Commerce, Inc., Strainz, Inc. and Voice Telecom.